Figure 1 | Scientific Reports

Figure 1

From: Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Figure 1The alternative text for this image may have been generated using AI.

Production of an asymmetric anti-CD20 antibody (SBU-CD20: scFv-Fcknob—scFab-FcHole) and analysis of its CDC. (a) Expression cassette for SBU-CD20. Pink and white circles indicate a knob mutation (T366W) and hole mutations (T366S, L368A, and Y407), respectively. (b) Schematic showing the structure of SBU-CD20. (c) SDS-PAGE showing purified SBU-CD20, Lane 1: reduced SBU-CD20; Lane 2: nonreduced SBU-CD20. (d) C4d production of SBU-CD20 and rituximab. Error bars represent the SE (standard error) of three replicates. (e) CDC of rituximab, rituximab-KiH, and SBU-CD20 in rituximab-sensitive cell lines (Ramos and WSU-NHL) and a rituximab-resistant cell line (BJAB). Error bars represent standard error calculated from triplicate samples. P-values < 0.05, < 0.01, and > 0.05 are marked with *, **, and “n.s.” for not significant, respectively.

Back to article page